And Then There Were Two…
Up until now, this company has been a “one hit wonder.” It's a biotech company with a single drug in development. It's an important drug, though, one for treating a rare genetic disorder. It's in the late stages, where a flurry of paperwork is submitted to regulatory authorities for marketing approval and the Washington deciders decide. Right now, it's a waiting game in both Europe and the U.S.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.